top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hIL17A mice​
Strain Name
C57BL/6-Il17atm1(IL17A)Bcgen/Bcgen
Common Name  B-hIL17A mice
Background C57BL/6 Catalog number  110053
Aliases 
IL17A, CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17, interleukin 17A
NCBI Gene ID
16171

Protein Expression Analysis

from clipboard

Analysis of spleen leukocytes cell subpopulations in B-hIL17A mice

from clipboard

from clipboard


Analysis of spleen leukocyte subpopulations by FACS.
Splenocytes were isolated from female C57BL/6 and B-hIL17A mice (n=3, 6 week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for CD45 population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hIL17A mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL17A in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in spleen. Values are expressed as mean ± SEM.

Analysis of spleen T cell subpopulations in B-hIL17A mice


from clipboard

from clipboard


Analysis of spleen T cell subpopulations by FACS.
Splenocytes were isolated from female C57BL/6 and B-hIL17A mice (n=3, 6 week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8+ T cells, CD4+ T cells and Treg cells in homozygous B-hIL17A mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL17A in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell sub types in spleen. Values are expressed as mean ± SEM.

Analysis of blood leukocytes cell subpopulations in B-hIL17A mice


from clipboard

from clipboard


Analysis of blood leukocyte subpopulations by FACS.
Blood cells were isolated from female C57BL/6 and B-hIL17A mice (n=3, 6 week-old). Flow cytometry analysis of the blood leukocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for CD45 population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hIL17A mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL17A in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in blood. Values are expressed as mean ± SEM.

Analysis of blood T cell subpopulations in B-hIL17A mice

from clipboard

from clipboard


Analysis of blood T cell subpopulations by FACS.
Blood cells were isolated from female C57BL/6 and B-hIL17A mice (n=3, 6 week-old). Flow cytometry analysis of the leukocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8+ T cells, CD4+ T cells and Treg cells in homozygous B-hIL17A mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL17A in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell sub types in blood. Values are expressed as mean ± SEM.


Blood routine test in B-hIL17A mice


from clipboard


Complete blood count (CBC). 

Blood from female C57BL/6 and B-hIL17A mice (n=3, 6 week-old) was collected and analyzed for CBC. There was no differences among any measurement between C57BL/6 and B-hIL17A mice, indicating that introduction of hIL17A in place of its mouse counterpart does not change blood cell composition and morphology. Values are expressed as mean ± SEM.


Blood chemistry of B-hIL17A mice

from clipboard



Blood chemistry tests of B-hIL17A mice. 
Serum from female C57BL/6 and B-hIL17A mice (n=3, 6 week-old) was collected and analyzed for levels of ALT and AST. There was no differences on either measurement between C57BL/6 and B-hIL17A mice, indicating that introduction of hIL17A in place of its mouse counterpart does not change ALT and AST levels or health of liver. Values are expressed as mean ± SEM.




MS/EAE model

Schematic of EAE model

Experimental Autoimmune Encephalomyelitis (EAE) is an induced demyelinating disease model that closely resembles the progression and symptoms of the human neurological disease Multiple Sclerosis (MS).

from clipboard

Clinical score of EAE model

from clipboard

EAE induction by MOG35–55/CFA Emulsion PTX in 10-week-old B-hIL17A mice. Data are expressed as mean ± SEM from a typical experiment (n = 5 except n = 4 for B-hIL17A-F PBS). MOG: myelin-oligodendrocyte glycoprotein; PTX: pertussis toxin. F: female; M: male.


H&E staining and IHC staining in mouse EAE model

from clipboard

Local inflammation of the CNS in B-hIL17A mice (female,n=5) during EAE. On day 45 after MOG/CFA and PTx immunization, spinal cords were removed. The tissue sections were stained with H&E(A,B) and IHC (C,D)(Green, MBP; Blue, DAPI). The sections at the lumbar level are shown. The results showed that the infiltration of inflammatory cells in the MOG group was significantly increased, and the myelin protein was greatly reduced.


IL17A+ cells in lymph node of EAE model

from clipboard

IL-17 was primarily produced by CD4 Th17 cells during the development of EAE. To detect IL-17 production,  cells from lymph node of B-hIL17A mice(female,n=5) immunized with MOG/CFA were stimulated for 6 hours by PMA and ionomycin in the presence of brefeldin A. IL-17-producing cells were analyzed by FACS, along with IFNg. The percentage of IL-17+CD3+CD4+ T cells in CD3+CD4+ T cells was increased in response to MOG immunization in B-hIL17A mice (left panel).  So was percentage of IFNg+ T cells.


IL17A+ cells in CNS of EAE model

from clipboard

IL-17 was primarily produced by CD4 Th17 cells during the development of EAE. To detect IL-17 production,  cells from CNS(Brain cell) of B-hIL17A mice(female,n=5) immunized with MOG/CFA were stimulated for 6 hours by PMA and ionomycin in the presence of brefeldin A. IL-17-producing cells were analyzed by FACS, along with IFNg. The percentage of IL-17+CD3+CD4+ T cells in CD3+CD4+ T cells was increased in response to MOG immunization in B-hIL17A mice (left panel).  So was percentage of IFNg+ T cells.


hIL17A Ab efficacy evaluation(B-hIL17A mice)


from clipboard

hIL17A Ab efficacy evaluation(B-hIL17A mice)

from clipboard

EAE induction by MOG35–55/CFA Emulsion PTX in B-hIL17A mice. The clinical score and body weight was collected after the treatment of anti-hIL17A antibody. After treatment of anti-hIL17A antibody, the clinical score level was much lower than the control in homozygous B-hIL17A mice.Data are expressed as mean ± SEM from a typical experiment (n = 6). MOG: myelin-oligodendrocyte glycoprotein; PTX: pertussis toxin. 


Imiquimod-Induced Psoriasis Model

Experimental schedule for induction of psoriasis-like skin lesions and in vivo efficacy of anti-human IL17A antibody 

from clipboard

In vivo efficacy of anti-human IL17A antibodies in psoriasis model induced in B-hIL17A mice


from clipboard


IMQ-induced skin inflammation in B-hIL17A mice phenotypically resembles psoriasis. 

Mice (female, 10 week-old, n=5) were scored daily for up to 6 days for body weight and clinical signs of skin inflammation following treatment with imiquimod (IMQ) cream. Mice in each group were treated with different dose of ixekizumab produced in house. Doses are shown in legend. (A) Phenotypical presentation of mouse back skin after 6 days of treatment. (B) Body weight changes during treatment. (C-D) Erythema and scaling score of the back was scored daily on a scale from 0 to 4. Additionally, the cumulative score (erythema plus scaling) is depicted. Values are expressed as mean ± SEM.


In vivo efficacy of anti-human IL17A antibodies in psoriasis model induced in B-hIL17A mice

from clipboard


Dose dependent effects of BsAbs on keratinocyte proliferation and inflammatory cell infiltration in IMQ induced psoriasis-like skin lesions in B-hIL17A mice. 

Back skin was collected at the endpoint and stained with Hematoxylin and eosin (H&E). (A) H&E staining of the back skin. (B) Epidermal thickness of the mice. (C) Histological changes were scored on a scale from 0 to 11. Results indicated that therapeutic effects of ixekizumab (in house) on psoriasis-like skin lesions in B-hIL17A mice were dose dependent, confirming that B-hIL17A mice provide a powerful model for in vivo evaluation of anti-human IL17A bispecific antibodies. Values are expressed as mean ± SEM.


In vivo efficacy of anti-human IL17A antibodies in psoriasis model induced in B-hIL17A mice

from clipboard

IMQ-induced skin inflammation in B-hIL17A mice phenotypically resembles psoriasis. 

Mice (female, 8 week-old, n=6) were scored daily for up to 6 days for body weight and clinical signs of skin inflammation following treatment with imiquimod (IMQ) cream. Mice in each group were treated with different doses of Secukinumab (commercial drug). (A) Experimental schedule for induction of psoriasis-like skin lesions in B-hIL17A mice. (B) Phenotypical presentation of mouse back skin at day0 and day 5. (C) Body weight changes during treatment. (D-E) Erythema and scaling score of the back was scored daily. Additionally, the cumulative score (erythema plus scaling) is depicted. Values are expressed as mean ± SEM. 


In vivo efficacy of anti-human IL17A antibodies in psoriasis model induced in B-hIL17A mice


from clipboardfrom clipboard

Dose dependent effects of antibodies on keratinocyte proliferation and inflammatory cell infiltration in IMQ induced psoriasis-like skin lesions in B-hIL17A mice. 

Back skin was collected at the endpoint and stained with Hematoxylin and eosin (H&E). (A) H&E staining of the back skin. (B) Histological changes were scored. (C) Epidermal thickness of the mice. Results indicated that therapeutic effects of Secukinumab (commercial drug) on psoriasis-like skin lesions in B-hIL17A mice were dose dependent, confirming that B-hIL17A mice provide a powerful model for in vivo evaluation of anti-human IL17A antibodies. Values are expressed as mean ± SEM.